SCHEMBL10279119

SCHEMBL10279119

CCc1ccc(-c2cc3ncccn3n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
THRB P10828 1/20 0.50
NPC1 O15118 7/20 0.49
RAB9A P51151 7/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
APOBEC3A P31941 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45
SYK P43405 1/20 0.44
GAA P10253 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HIF1A Q16665 1/20 0.40
PARP1 P09874 1/20 0.40
TP53 P04637 1/20 0.40
DYRK1A Q13627 1/20 0.40
SLC6A7 Q99884 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10279220 0.84 NPC1 (0.46) MAPTSMN1; SMN2THRBNPC1RAB9A
SCHEMBL1665644 0.82 APOBEC3A (0.54) MAPTSMN1; SMN2THRBNPC1RAB9A
SCHEMBL4154898 0.80 MAPT (0.49) MAPTSMN1; SMN2NPC1RAB9AAPOBEC3A
SCHEMBL5052722 0.80 RAB9A (0.49) MAPTSMN1; SMN2NPC1RAB9AAPOBEC3A
SCHEMBL5060955 0.80 APOBEC3A (0.49) MAPTTHRBNPC1RAB9AAPOBEC3A
SCHEMBL1015835 0.79 DYRK1A (0.62) MAPTNPC1RAB9AAPOBEC3AAPOBEC3G
SCHEMBL10236247 0.79 APOBEC3A (0.45) MAPTSMN1; SMN2NPC1RAB9AAPOBEC3A
SCHEMBL30708692 0.78 APOBEC3A (0.61) MAPTNPC1RAB9AAPOBEC3AAPOBEC3G
Hydrochloric Acid SCHEMBL25276515 0.78 DYRK1A (0.60) MAPTNPC1RAB9AAPOBEC3AAPOBEC3G
SCHEMBL5946565 0.76 APOBEC3A (0.49) MAPTSMN1; SMN2THRBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193372-B2 Phosphothiophene and phosphothiazole HCV polymerase inhibitors IDENIX PHARMACEUTICALS, INC. (US) 2012-06-05 US disclosed
US-20100233123-A1 PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS IDENIX PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100233123-A1 PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS PPP3CB, POLR2E, PSAT1 MAPT 1176/4885SMN1; SMN2 4434/4885THRB 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.